Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China Will Not Bring Charges against GlaxoSmithKline as a Company

publication date: Nov 5, 2013
China will not indict GlaxoSmithKline as a corporation following the company’s China bribery scandal, according to Reuters, who talked with both government and company officials. Several of its top executives – presumably including the four people already in custody – will face charges. The indictments will not reach as high as Mark Reilly, who was head of the company’s China operation at the time the alleged bribes occurred. If this scenario plays out, it will buttress GSK’s assertion that the scandal was caused by a relatively few company officials, who were operating outside of well-articulated company guidelines. More details....

Stock Symbol: (NYSE: GSK)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital